Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.52 |
| ▸ | JAK2 | O60674 | 6/20 | 0.51 |
| ▸ | JAK1 | P23458 | 6/20 | 0.51 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954374 | 0.80 | JAK2 (0.49) | CSNK2A1JAK2JAK1ULK1ROCK1 | |
| SCHEMBL28775976 | 0.77 | DYRK1A (0.66) | CSNK2A1ULK1ROCK1FLT3CCNA2 | |
| SCHEMBL4007094 | 0.76 | FLT3 (0.72) | CSNK2A1JAK2JAK1ULK1ROCK1 | |
| SCHEMBL4531693 | 0.75 | FLT3 (0.55) | CSNK2A1JAK2JAK1ULK1FLT3 | |
| SCHEMBL12193634 | 0.74 | KDM4E (0.53) | CSNK2A1JAK2JAK1ULK1FLT3 | |
| SCHEMBL4510038 | 0.73 | CSNK2A1 (0.51) | CSNK2A1JAK2JAK1ROCK1FLT3 | |
| SCHEMBL952349 | 0.72 | CSNK2A1 (0.69) | CSNK2A1FLT3CCNA2CDK2CCNA1 | |
| SCHEMBL28944082 | 0.72 | DYRK1A (0.69) | FLT3WNT1DYRK1A | |
| SCHEMBL28775990 | 0.71 | DYRK1A (0.61) | JAK2FLT3WNT1DYRK1A | |
| SCHEMBL2468351 | 0.70 | YTHDC1 (0.65) | CSNK2A1JAK2JAK1ULK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4762543-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | claimed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | claimed |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | CSNK2A1 2594/4885JAK2 3068/4885JAK1 3595/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | CSNK2A1 2594/4885JAK2 3068/4885JAK1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.